- Home
- RUM vs IBRX Comparison
RUM vs IBRX Comparison
Compare RUM & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- IBRX
- Stock Information
- Founded
- RUM 2013
- IBRX 2014
- Country
- RUM United States
- IBRX United States
- Employees
- RUM N/A
- IBRX N/A
- Industry
- RUM Computer Software: Prepackaged Software
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RUM Technology
- IBRX Health Care
- Exchange
- RUM Nasdaq
- IBRX Nasdaq
- Market Cap
- RUM 2.0B
- IBRX 1.9B
- IPO Year
- RUM N/A
- IBRX N/A
- Fundamental
- Price
- RUM $12.90
- IBRX $2.94
- Analyst Decision
- RUM Buy
- IBRX Strong Buy
- Analyst Count
- RUM 3
- IBRX 3
- Target Price
- RUM $14.00
- IBRX $13.58
- AVG Volume (30 Days)
- RUM 12.9M
- IBRX 6.3M
- Earning Date
- RUM 11-12-2024
- IBRX 11-12-2024
- Dividend Yield
- RUM N/A
- IBRX N/A
- EPS Growth
- RUM N/A
- IBRX N/A
- EPS
- RUM N/A
- IBRX N/A
- Revenue
- RUM $85,651,775.00
- IBRX $7,332,000.00
- Revenue This Year
- RUM $19.36
- IBRX $2,515.60
- Revenue Next Year
- RUM $18.49
- IBRX $766.19
- P/E Ratio
- RUM N/A
- IBRX N/A
- Revenue Growth
- RUM 6.36
- IBRX 1218.71
- 52 Week Low
- RUM $3.39
- IBRX $2.28
- 52 Week High
- RUM $17.40
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- RUM 59.04
- IBRX 48.30
- Support Level
- RUM $10.06
- IBRX $2.28
- Resistance Level
- RUM $11.65
- IBRX $2.54
- Average True Range (ATR)
- RUM 1.31
- IBRX 0.25
- MACD
- RUM -0.26
- IBRX 0.10
- Stochastic Oscillator
- RUM 38.69
- IBRX 64.71
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.